ACRV Logo

Acrivon Therapeutics, Inc. Common Stock (ACRV) 

NASDAQ$5.44
Market Cap
$169.38M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
30 of 924
Rank in Industry
23 of 527

ACRV Insider Trading Activity

ACRV Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$20,000,5001100
Sells
$000

Related Transactions

PERCEPTIVE ADVISORS LLC10 percent owner1$20M0$0$20M

About Acrivon Therapeutics, Inc. Common Stock

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate …

Insider Activity of Acrivon Therapeutics, Inc. Common Stock

Over the last 12 months, insiders at Acrivon Therapeutics, Inc. Common Stock have bought $20M and sold $0 worth of Acrivon Therapeutics, Inc. Common Stock stock.

On average, over the past 5 years, insiders at Acrivon Therapeutics, Inc. Common Stock have bought $33.68M and sold $97,579 worth of stock each year.

Highest buying activity among insiders over the last 12 months: PERCEPTIVE ADVISORS LLC (10 percent owner) — $20M.

The last purchase of 2,353,000 shares for transaction amount of $20M was made by PERCEPTIVE ADVISORS LLC (10 percent owner) on 2024‑04‑11.

List of Insider Buy and Sell Transactions, Acrivon Therapeutics, Inc. Common Stock

2024-04-11PurchasePERCEPTIVE ADVISORS LLC10 percent owner
2.35M
8.4743%
$8.50$20M-21.10%
2023-06-26SaleChione Ltd10 percent owner
16
<0.0001%
$12.93$207-48.66%
2023-06-15SaleChione Ltd10 percent owner
2,056
0.0106%
$12.14$24,960-39.33%
2023-06-14SaleChione Ltd10 percent owner
893
0.0046%
$12.13$10,832-38.40%
2023-06-13SaleChione Ltd10 percent owner
3,000
0.0156%
$12.30$36,900-40.28%
2023-06-12SaleChione Ltd10 percent owner
2,000
0.0105%
$12.34$24,680-40.91%
2022-11-17PurchaseRA CAPITAL MANAGEMENT, L.P.
3.39M
17.9519%
$12.50$42.37M-21.95%
2022-11-17PurchaseChione Ltd10 percent owner
400,000
2.1185%
$12.50$5M-21.95%
Total: 8
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
PERCEPTIVE ADVISORS LLC10 percent owner
5360858
17.2174%
$29.16M10
RA CAPITAL MANAGEMENT, L.P.
4384206
14.0807%
$23.85M10<0.0001%
Chione Ltd10 percent owner
3848632
12.3606%
$20.94M15<0.0001%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$2,924,567
72
-4.87%
$157.74M
$613,304,943
46
11.85%
$191.55M
$79,019,806
27
7.24%
$165.26M
$6,915,275
21
-32.61%
$158.47M
$2,484,989
17
-17.86%
$156.9M

ACRV Institutional Investors: Active Positions

Increased Positions30+53.57%752,160+3.28%
Decreased Positions20-35.71%479,087-2.09%
New Positions12New443,594New
Sold Out Positions6Sold Out200,370Sold Out
Total Postitions66+17.86%23M+1.19%

ACRV Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Ra Capital Management, L.P.$44,288.0026.91%8.34M00%2024-12-31
Perceptive Advisors Llc$28,466.0017.29%5.36M00%2024-12-31
Sands Capital Ventures, Llc$11,271.006.85%2.12M00%2024-12-31
Citadel Advisors Llc$11,255.006.84%2.12M-20,982-0.98%2024-12-31
Blackrock, Inc.$5,021.003.05%945,496+158,514+20.14%2024-12-31
Wellington Management Group Llp$4,716.002.87%888,13000%2024-12-31
Vanguard Group Inc$3,566.002.17%671,625+34,087+5.35%2024-12-31
Marshall Wace, Llp$3,174.001.93%597,794-212,065-26.18%2024-12-31
Acorn Capital Advisors, Llc$2,152.001.31%405,237+405,237New2024-12-31
Geode Capital Management, Llc$1,600.000.97%301,389-714-0.24%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.